| [1] |
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73.
|
| [2] |
Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma[J]. J Hepatol, 2009, 51(5): 890-897.
|
| [3] |
Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy[J]. Hepatology, 2013, 57(1): 399-408.
|
| [4] |
Huang G, Lau WY, Shen F, et al. Preoperative hepatitis B virus DNA level is a risk factor for postoperative liver failure in patients who underwent partial hepatectomy for hepatitis B-related hepatocellular carcinoma[J]. World J Surg, 2014, 38(9): 2370-2376.
|
| [5] |
Huang G, Yang Y, Shen F, et al. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load[J]. Ann Surg Oncol, 2013, 20(5):1482-1490.
|
| [6] |
Lee JI, Kim JK, Chang HY, et al. Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus[J]. J Gastroenterol Hepatol, 2014, 29(5): 1019-1027.
|
| [7] |
Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy[J]. Br J Cancer, 2004, 90(7):1306-1311.
|
| [8] |
Huang W, Zhang W, Fan M, et al. Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma[J]. Cancer Sci, 2014, 105(6): 697-703.
|
| [9] |
Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization[J]. Hepatology, 2006, 43(2):233-240.
|
| [10] |
Kim JH, Park JW, Kim TH, et al. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2007, 69(3): 813-819.
|
| [11] |
Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy[J]. Ann Oncol, 2004, 15(11):1661-1666.
|
| [12] |
Urata Y, Kubo S, Takemura S, et al. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma[J]. J Hepatobiliary Pancreat Sci, 2012, 19(6):685-696.
|
| [13] |
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 351(15):1521-1531.
|
| [14] |
Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group[J]. N Engl J Med, 1998, 339(2):61-68.
|
| [15] |
Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B[J]. N Engl J Med, 2007, 357(25):2576-2588.
|
| [16] |
Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology, 2010, 52(3):886-893.
|
| [17] |
Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2011, 33(10):1104-1112.
|
| [18] |
Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection[J]. JAMA, 2012, 308(18):1906-1914.
|
| [19] |
Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function[J]. Intern Med, 2009, 48(1):11-17.
|
| [20] |
Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study[J]. J Clin Oncol, 2013, 31(29):3647-3655.
|
| [21] |
Lao XM, Luo G, Ye LT, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma[J]. Liver Int, 2013, 33(4):595-604.
|
| [22] |
Dan JQ, Zhang YJ, Huang JT, et al. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study[J]. Eur J Surg Oncol, 2013, 39(8):865-872.
|
| [23] |
Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors[J]. J Hepatol, 2013, 58(1):89-97.
|
| [24] |
中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2010年版) [J]．中华内科杂志，2011，50(2):168-179．
|
| [25] |
中华人民共和国卫生部．原发性肝癌诊疗规范(2011年版)[J]．临床肝胆病杂志，2011, 27(11):1141-1159.
|
| [26] |
肝细胞癌抗病毒治疗专家组．HBV/HCV相关性肝细胞癌抗病毒治疗专家共识[J]．临床肿瘤学杂志，2014，19(5):452-459.
|
| [27] |
Sun HC, Zhang W, Qin LX, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma[J]. J Hepatol, 2007, 47(5): 684-690.
|
| [28] |
Na GH, Kim DG, Han JH, et al. Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation[J]. J Gastroenterol Hepatol, 2014, 29(1):151-156.
|
| [29] |
Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B[J]. Gastroenterology, 2003, 125(6):1714-1722.
|
| [30] |
Marcellin P, Chang TT, Lim SG,et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology, 2008, 48(3):750-758.
|
| [31] |
Huang G, Lai EC, Lau WY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels[J]. Ann Surg, 2013, 257(3):490-505.
|
| [32] |
Cao L, Wu C, Shi H, et al. Coexistence of hepatitis B virus quasispecies enhances viral replication and the ability to induce host antibody and cellular immune responses[J]. J Virol, 2014, 88(15):8656-8666.
|